GHSR
Growth hormone secretagogue receptor type 1
As of the edition of 20 October 2026, GHSR (growth hormone secretagogue receptor type 1, UniProt Q92847) has 10 drugs tested at it and 12 companies on the list, 6 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q92847
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 11
- Disease areas
- Digestive system; Hormones; Nutrition and metabolism; Cancer; Lungs and airways; Mental health; Nervous system; Chemically induced
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 5 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Anamorelin | Marketed | Phase 3 | none listed |
| Ulimorelin | Went quiet | Phase 3 | none listed |
| Ibutamoren | Stopped | Phase 2 | none listed |
| Relamorelin | Stopped | Phase 3 | none listed |
| PF-5190457 | Stopped | Phase 2 | none listed |
| TZP-102 | Stopped | Phase 2 | none listed |
| AC01 | Active | Phase 2 | none listed |
| Macimorelin | Marketed | Phase 3 | Ends 2030 |
| Capromorelin | Stopped | Phase 2 | none listed |
| Ipamorelin | Went quiet | Phase 2 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Pfizer | Route A |
| AbbVie | Route A |
The other 9 companies at GHSR
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at GHSR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.